Evidence map›Paper›PMID 40325945›Full record

ArticlePediatric pulmonology2025

Cystic Fibrosis Learning Network Telehealth Innovation Lab During the COVID-19 Pandemic: Impact on Access to Care, Outcomes, and a New CF Care Model.

Dana Albon, Thida Ong, Bethany Horton, David Brighton, Shiyi Shen, Rhonda List, Nicholas Antos, Fadi Asfour, Ella Balasa, Danielle Beachler and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric pulmonology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Transforming Care Models in Cystic Fibrosis: A Review.Healthcare (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Dana AlbonDepartment of Internal Medicine, Division of Pulmonary and Critical Care, University of Virginia, Charlottesville, Virginia, USA.
Thida OngSeattle Children's Hospital, Pulmonary and Sleep Medicine, University of Washington School of Medicine, Pediatrics, Seattle, Washington, USA.ORCID http://orcid.org/0000-0002-4498-684X
Bethany HortonDepartment of Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA.
David BrightonDepartment of Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA.
Shiyi ShenDepartment of Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA.
Rhonda ListDepartment of Internal Medicine, Division of Pulmonary and Critical Care, University of Virginia, Charlottesville, Virginia, USA.
Nicholas AntosDepartment of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID http://orcid.org/0000-0002-7380-120X
Fadi AsfourDepartment of Pediatrics, The University of Utah, Salt Lake City, Utah, USA.
Ella BalasaVirginia Commonwealth University, Pulmonary and Critical Care, Richmond, Virginia, USA.
Danielle BeachlerDepartment of Pediatrics, Dell Children's Medical Center of Central Texas, Austin, Texas, USA.
Cori DainesUniversity of Arizona Medical Center - University Campus, Pediatrics, Tucson, Arizona, USA.
Deborah FrohDepartment of Pediatrics, University of Virginia, Charlottesville, Virginia, USA.
Catherine KierDepartment of Pediatrics, Stony Brook University, Stony Brook, New York, USA.
Samya NasrDepartment of Pediatrics, University of Michigan Health System, Ann Arbor, Michigan, USA.ORCID http://orcid.org/0000-0002-4124-316X
Meghana SatheUT Southwestern Medical Center, Division of Pediatric Gastroenterology and Nutrition, Dallas, Texas, USA.ORCID http://orcid.org/0000-0002-7088-8530
Gregory SawickiDivision of Respiratory Diseases, Children's Hospital Boston, Boston, Massachusetts, USA.ORCID http://orcid.org/0000-0003-3356-709X
Michael SchechterDepartment of Pediatrics, Virginia Commonwealth University, Richmond, Virginia, USA.
George SolomonUniversity of Alabama at Birmingham, Medicine, Gregory Fleming James Cystic Fibrosis Research Center, Birmingham, Alabama, USA.
Michael PowersDepartment of Pediatrics, Oregon Health & Sciences University, Portland, Oregon, USA.

Funding

This study was grant support by CFF 004212322 - Albon; CFF SEID19AB0.
6 · The paper itself

Abstract

backgroundCystic fibrosis (CF) is a chronic genetic disorder requiring regimented visits for maintenance of care. The COVID-19 pandemic accelerated the accessibility of telehealth (TH) and forced a trial of incorporating remote care into routine CF care. The CF Learning Network (CFLN) organized for data sharing into a telehealth innovation lab (TH-iLab) to improve access to the interdisciplinary care team and co-produced shared agenda-setting.

methodsAll persons with CF (PwCF) with a CF diagnosis in the CF Foundation Registry (CFFPR) from 1/2020-12/2021 were included and categorized into CFLN TH-iLab, CFLN TH-iLab non-participants, and non-CFLN programs. HYPOTHESIS: standardized TH implementation in the CFLN TH-iLab is associated with increased access to the CF care model and results in similar lung function and nutrition health outcomes.

resultsIn 2020 and 2021, the average number of TH visits per person per year and the percentage of PwCF with one or more TH visits per year were higher in the CFLN TH-iLab than in the other groups. Lung function was highest in PwCF, followed by a program that was part of the CFLN TH-iLab in 2020 and 2021. Anthropometric measurements, spirometry, and attainment of microbiology cultures were similar among all three groups. Access to interdisciplinary care was highest in the CFLN non-TH-iLab group.

conclusionIntegrating TH into CF care in the CFLN TH-iLab provided access to care during the COVID-19 pandemic without compromising clinical outcomes. Further research on optimizing the telehealth experience for PwCF can help better understand TH's long-term impact on CF care.

Indexed as

COVID-19Cystic FibrosisHealth Services AccessibilityTelemedicineAdolescentAdultChildFemaleHumansMalePandemicsRegistriesSARS-CoV-2cystic fibrosiscystic fibrosis learning networkinnovation laboratoryquality improvementtelehealth

Identifiers

PMID40325945
PMCPMC12052861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.